Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995326 | 0.78 | LTA4H (0.55) | LTA4HRAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL21087778 | 0.77 | MAPT (0.42) | LTA4HRAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL7812474 | 0.77 | LTA4H (0.41) | LTA4HRAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL15400049 | 0.76 | FABP3 (0.49) | LTA4HADRA1DADRA1AADRA1BALDH1A1 | |
| Hydrogen Sulfide SCHEMBL752785 | 0.75 | LTA4H (0.53) | LTA4HRAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL8927888 | 0.75 | MAPT (0.52) | ACHERAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL4325551 | 0.74 | HCRTR1 (0.48) | LTA4HADRA1DADRA1AADRA1BRAB9A | |
| SCHEMBL3626478 | 0.72 | RAB9A (0.61) | LTA4HRAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL29882784 | 0.72 | LTA4H (1.00) | LTA4HADRA1DADRA1AADRA1BRAB9A | |
| SCHEMBL21067981 | 0.72 | LTA4H (1.00) | LTA4HADRA1DADRA1AADRA1BRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063038-B2 | vasopressin V2 receptor agonists for treating nocturnal enuresis, nocturia, diabetes insipidus, urinary incontinence and bleeding disorders; {1-[4-(5H,11H-Benzo[e]pyrrolo[1,2- alpha ][1,4]diazepine-10-carbonyl)-2-methylbenzylcarbamoyl]-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl}acetic acid ethyl ester | VANTIA LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-8063038-B2 | vasopressin V2 receptor agonists for treating nocturnal enuresis, nocturia, diabetes insipidus, urinary incontinence and bleeding disorders; {1-[4-(5H,11H-Benzo[e]pyrrolo[1,2- alpha ][1,4]diazepine-10-carbonyl)-2-methylbenzylcarbamoyl]-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl}acetic acid ethyl ester | VANTIA LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| EP-1778677-B1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | VANTIA LTD (GB) | 2010-02-03 | — | — | EP | disclosed |
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | FERRING B.V. | 2008-09-25 | — | — | US | disclosed |
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | FERRING B.V. | 2008-09-25 | — | — | US | disclosed |
| WO-2006018443-A1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | FERRING B.V. (NL) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | AVPR2, AVPR1A, AVPR1B | LTA4H 1187/4885ADRA1D 48/4885ADRA1A 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.